← Back to Home

Turning AI-Designed Proteins into Experimental Tools: Monod Bio Licenses Technologies to SignalChem for Custom Assay Development

A non-exclusive license brings a light-emitting enzyme and target-binding proteins into contract research services. The collaboration expands the commercial uses of AI protein design, but improvements in assay performance and R&D efficiency still require concrete supporting data.

By SURL BioNews

Drug discovery relies on experimental tools that turn biological reactions into readable signals, and AI-designed proteins are now entering this part of the process. On August 26, 2026, Monod Bio announced that it had granted SignalChem Biotech a non-exclusive license to two protein technologies, enabling the latter to develop customized luminescence assays and protein fusion services for research clients.

According to Monod Bio’s announcement and Scientist Live’s coverage of the same event, the license covers LuxSit luciferase technology and NovoBodies binding proteins. SignalChem is a wholly owned subsidiary of Sino Biological, and the scope of use granted under this license is to provide research-use services to third-party clients. The announcement did not disclose licensing fees, milestone payments, or royalty terms.

The two technologies play different roles in experiments. LuxSit is a light-emitting enzyme designed from scratch that can be used in biosensors to provide a measurable light signal; NovoBodies are compact binding proteins that recognize specific targets. According to the company, the latter are highly stable. Such components help researchers develop assays suited to their own research questions, while actual performance still depends on the target, samples, and design approach.

The collaboration also gives Monod Bio another channel for reaching research clients. CEO Daniel Silva Manzano described the deal as an extension of the “Monod Inside” model: integrating designed proteins into commercial products and services through partners. For SignalChem, the license expands the tools available for its contract research services. Sino Biological business executive Rob Burgess said the company hoped this would improve research efficiency; this is the company’s expectation, rather than a published comparative result.

The publicly available information currently remains focused on the licensing arrangement. Neither the announcement nor coverage of the same event provided specific targets, numbers of samples tested, detection limits, or comparative data against existing methods for these custom assays. They also did not describe the training data used for the AI design model. The establishment of the collaboration alone therefore does not establish that the new tools can improve the quality of drug candidates or determine how much R&D time they might save. The license is limited to research use and does not mean that the related assays have received approval for clinical diagnosis.

This deal illustrates one route for AI protein design to enter research services: a tool supplier turns molecular components into experimental methods that clients can use. Whether this generates sustained demand will depend on performance, reproducibility, and cost across different applications. The announcement also noted that revenue from the related business is not expected to have a material impact on Sino Biological’s overall financial performance, suggesting that, at this stage, it is better understood as an expansion of service capabilities.

References

  1. News-Medical
  2. Monod Bio
  3. Scientist Live